c-LEcta Continues Its Growth in 2020 and Increases Its EBITDA Above Average Sales for 2020 to exceed the EUR 10 million mark for the first time EBITDA margin in the double-digit percentage range in 2020 Very strong growth in sales and a further increase in the EBITDA margin expected for 2021 c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its growth in 2020 in what turned out to be a challenging year overall. Besides increasing its sales to more than EUR 10 million, an EBITDA margin in the double-digit percentage range is already expected this year. Management also expects increases in sales and the EBITDA margin in 2021. This is due to well-filled order books and high-growth products.